• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4606055)   Today's Articles (848)   Subscriber (49373)
Number Citation Analysis
1
Amiri-Kordestani L, Jawed I, Wilkerson J, Stein WD, Bates SE, Swain SM, Fojo AT. Determining the rate of tumor growth and decay in patients with metastatic breast cancer as an early efficacy endpoint: A study assessing ixabepilone efficacy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
2
Gramza AW, Wells SA, Balasubramaniam S, Fojo AT. Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5565] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
3
Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
4
Amiri-Kordestani L, Jawed I, Wilkerson J, Stein WD, Fojo AT, Swain SM, Bates SE. Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
5
Jawed I, Amiri-Kordestani L, Velarde M, Adams K, Balasubramaniam S, Reynolds J, Pacak K, Fojo AT. High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
6
Wilkerson J, Stein WD, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE. Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-α): Analysis of the pivotal randomized trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4597] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
7
Fojo AT, Stein WD, Wilkerson J, Bates SE. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
8
Gulley JL, Stein WD, Schlom J, Madan RA, Dahut WL, Figg WD, Ning YM, Price D, Bates SE, Fojo AT. A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4657] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
9
Vidaurre T, Wilkerson J, Bates SE, Simon R, Fojo AT. Value of stable disease (SD) in drug development of targeted therapies (TGT). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
10
Menefee ME, Huang H, Edgerly M, Kotz H, Merino M, Balis FM, Chen CC, Robey R, Bates SE, Fojo AT. Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2543] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
11
Ning YM, Arlen PM, Gulley JL, Stein WD, Fojo AT, Latham L, Wright JJ, Parnes H, Figg WD, Dahut WL. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5000] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
12
Piekarz R, Luchenko V, Draper D, Wright JJ, Figg WD, Fojo AT, Bates SE. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3571] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
13
Huang H, Menefee ME, Edgerly M, Kotz H, Poruchynsky M, Stein WD, Bates SE, Fojo AT. Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5053] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
14
Fojo AT, Stein WD, Yang J, Bates SE. Effect of bevacizumab (Bev) on the growth rate constants of renal carcinoma (RCC) tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
15
Samnotra V, Vassilopoulou-Sellin R, Fojo AT, Oh WK, LaRocca RV, Ernstoff MS, Memoli VA, Cole BF, Quinn DI, Simmons PA, Tretter CP. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15527] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
16
Menefee M, Edgerly M, Velarde M, Herbert K, Fojo AT. The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.12033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
17
Menefee ME, Fan C, Edgerly M, Draper D, Chen C, Robey R, Balis F, Figg WD, Bates S, Fojo AT. Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3093] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
18
Fojo AT, Menefee ME, Poruchynsky M, Edgerly M, Mickley L, Li Ning Tapia E, Merino M, Balis F, Bates S. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4541] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
19
Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 2002;31:6366-72. [PMID: 1352990 DOI: 10.1021/bi00143a002] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
20
Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, Bates SE. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 1997;89:3795-800. [PMID: 9160686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
21
Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J, Hwang J. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res 1997;57:1516-22. [PMID: 9108454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
22
Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 1997;37:123-8. [PMID: 9055138 DOI: 10.1002/j.1552-4604.1997.tb04770.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
23
Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20. [PMID: 8674056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
24
Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B. Clinical reversal of multidrug resistance. Stem Cells 1996;14:56-63. [PMID: 8820952 DOI: 10.1002/stem.140056] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
25
Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, Chabner BA. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 1995;121:495-500. [PMID: 7559726 DOI: 10.1007/bf01197759] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
PrevPage 1 of 3 123Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA